Radiation and immunotherapy combo tested for lung cancer

NCT ID NCT03307759

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested the safety of giving a precise form of radiation (SABR) either before or after the immunotherapy drug pembrolizumab in 13 people with metastatic non-small cell lung cancer. The goal was to see if the combination caused severe side effects and whether it helped shrink tumors. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (immunotherapy) and stereotactic ablative body radiotherapy (SABR, a precise form of radiation)
What this could lead to
If successful, this could point toward a more effective way to combine radiation and immunotherapy for advanced lung cancer, potentially improving tumor shrinkage and survival.
What could go wrong
This is a very early (phase 1), small (13 participants) terminated trial, so results are limited and may not be reliable. The combination may cause severe side effects (grade 3 toxicities) and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.